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Hepatitis B viral mutants can emerge in patients as a
result of selection pressure from either immune response
or treatment options. Mutations that occur within the
immunodominant epitopes of hepatitis B surface antigen
(HBsAg) allow mutant virus to propagate in the presence of
a neutralizing immune response, while wild-type virus is
reduced to undetectable levels. HBsAg mutants present as
false-negative results in some immunoassays. An under-
standing of immunoassay reactivity with HBsAg mutants is
key to establishing an appropriate testing algorithm for hep-
atitis B virus detection programs.
O
ver the past decade, the importance of hepatitis B
virus (HBV) mutants has made a transition from an
academic phenomenon of unknown prevalence to a factor
for consideration during disease diagnosis. HBV infection
has a major effect on world health care: more than one
third of the world’s population has been infected at some
point; ≈350 million people are currently infected (1). This
immense worldwide reservoir of infection serves as the
basis for the generation of HBV mutants because of the
unique molecular biology of this virus. Since the late
l980s, we have seen the emergence of mutants across the
entire HBV genome as the virus responds to selective pres-
sures, such as vaccination and antiviral therapy. Viral
adaptation through mutation will continue as new treat-
ment options are employed and current treatment options
are expanded into areas of endemic infection. HBV mutant
surveillance and understanding of HBV mutant impact on
disease diagnosis will pose a challenge to global health
care for the foreseeable future. Thus, diagnosticians and
the healthcare industry need to increase their awareness of
HBV mutants and how these mutants may alter current
diagnostic and treatment algorithms. This article addresses
recent information concerning the emergence of hepatitis
B surface antigen (HBsAg) mutants, their impact on viral
antigen presentation, latest prevalence data, and discussion
of the issues associated with detection of mutants in
healthcare settings.
Mechanism of HBV Mutant Generation
HBV belongs to the genus Orthohepadnavirus, family
Hepadnaviridae. This virus has a small circular DNA
genome, ≈3.2 kb in length, that contains 4 genes with par-
tially overlapping open reading frames (ORFs). These
ORFs encode the polymerase protein (Pol gene); core anti-
gen and e antigen (C gene); large, medium, and small sur-
face-antigen proteins (S gene); and the X protein (X gene).
From a relatively small genome, these overlapping ORFs
generate 7 proteins. While this gene overlap may constrain
some viral variability, mutant or variant forms have been
identified for all 4 genes (2). HBV analysis has transi-
tioned from the serologic subtype classification of the
early 1970s to the more precise genotype genetic classifi-
cation. HBVhas been classified into 8 genotypes (A–H) on
the basis of intergenotypic difference of >8% in the entire
nucleotide sequence (3). HBV genotypes demonstrate geo-
graphic diversity. However, distinct genotypes have
evolved in more remote areas, as evidenced by genotype E,
localized in Madagascar, and genotype F, localized in
South America. This diversity of the HBV genome is gen-
erated by the same mechanism that drives the emergence
of mutants, replication.
The replication of HBV DNA proceeds through a RNA
reverse transcriptase intermediary step. HBV variants are
generated during this process. Since the reverse transcrip-
tase activity of the HBV polymerase protein lacks a proof-
reading function, random mis-incorporation of bases into
the replicating DNAstrand occurs. This mismatch leads to
the generation of multiple variant transcripts from a single
template and the formation of a quasispecies pool (4). This
quasispecies pool provides the source material for the
emergence of a mutant when selection pressure is applied
(5). A mutation selected for in 1 gene can potentially lead
to an amino acid change in the overlapping reading frame.
Replication of the hepatitis B virion is, therefore, the sole
requirement for generating these nucleotide mismatch
sequences. The number of viral particles generated in
some infected persons can be as high as 1011 viral particles
per day. Because of the polymerase reverse transcription
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base-pairing errors can be generated per day over the
3,200-bp genome (6). While most of these new sequences
are nonviable or fail to effectively compete with wild-type
virus, they provide a starting point for the emergence of
mutants when selection pressure is applied. HBV mutants
can be expected to emerge in any geographic area where
populations of infected persons are exposed to a selective
pressure. 
New treatment regimens developed over the past 2
decades have successfully reduced overall HBV infection
rates, but they have also exerted powerful selection pres-
sures for the emergence of HBV mutants. Treatments that
have selected for mutants include immunotherapy (vacci-
nation, administration of HBV immune globulin) and
nucleoside analogs (e.g., lamivudine, lobucavir, famci-
clovir, adefovir) to inhibit polymerase activity. These treat-
ment options can suppress wild-type HBV to undetectable
levels, allowing a mutant HBV strain to emerge as the pre-
dominant form. Emergence of a mutant species can be
monitored by using such techniques as real-time poly-
merase chain reaction (PCR) assays, restriction length
polymorphism assays, quantitative fragment analysis, and
primer extension assays. These powerful techniques can
detect trace mutant sequences in clinical samples with a
preponderance of wild-type virus, while conventional
DNAsequencing cannot (7). Mixed infection samples (i.e.,
low-level HBV chronic infections) that contain a prepon-
derance of wild-type HBsAg present a challenge to
immunoassay sensitivity, not epitope recognition. We only
address the detection of HBsAg mutants in clinical sam-
ples that appear to be homogenous and therefore specifi-
cally challenge immunoassay epitope recognition.
Replication-defective mutants, intracellular accumulation
of normally secreted antigens, and tissue localization can
also affect mutant detection in clinical samples. 
Surface Antigen Structure
The translational products of the surface antigen gene
consist of 3 proteins that have different initiation sites with
the same termination site. The most important of these pro-
teins, from a diagnostic standpoint, is the small HBsAg
(sHBsAg) protein, which is composed of 226 amino acids
(aa). sHBsAg is the major structural protein of the hepati-
tis B viral envelope. Most HBsAg in the plasma of HBV-
infected persons consists of 22-nm spherical particles
composed of ≈100 HBsAg monomers each (8). Initial
studies noted that HBsAg has a complex structure with dis-
continuous epitopes. The possibility of multiple antigenic
conformations or intermolecular epitopes cannot be ruled
out when considering surface antigen structure. This anti-
genic complexity has impeded elucidation of HBsAg
structure.
The HBsAg amino acid sequence contains a highly
conformational, hydrophilic domain from positions 100 to
160 referred to as the “a” determinant. The “a” determinant
represents the immunodominant region of HBsAg. The
reagents used in many HBsAg diagnostic assays are direct-
ed against epitopes in the “a” determinant. The “a” deter-
minant conformational epitopes are stabilized by a
backbone of conserved disulfide-bonded cysteine residues.
Alteration of residues in the “a” determinant can result in
reduced antigenicity and reduced levels of protein expres-
sion (9). Using a combination of conformational peptides
(10) and phage display experiments (11), we constructed a
working model of the “a” determinant (Figure). The key
features of this model include a large laminar loop stabi-
lized by bonding between cysteine residues 108–138 with
a fingerlike projection stabilized by disulfide-bonded
121–124 cysteine residues. While other cysteine residues
affect antigenicity when mutated, a double mutation of
these 121–124 cysteine residues has physical properties
similar to those of wild-type virus (12). These data indicate
that the fingerlike projection at aa 121–124 forms an epi-
tope that is relatively isolated from other substitutions in
the “a” determinant. The model also includes a second
loop, which projects from the viral membrane and is stabi-
lized by bonding between cysteine pairs 136–149 and
139–147. The human immune response to HBsAg is pri-
marily directed against disulfide-bonded conformational
epitopes of the “a” determinant and can be classified into a
limited number of epitopes (13–15). Alteration of these
conformational epitopes not only can result in failure to
neutralize viral infection but also can affect diagnostic
assay detection, depending on the epitopes recognized by
the assay reagent configuration.
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Figure. Gly/Arg 145 mutant in the projecting amino acid 139–147
antigenic loop of the “a” determinant. This mutant produces false-
negative results in some commercial assays. Image courtesy of
Y. C. Chen et al. (11).Surface Antigen Mutants
The initial description of an HBsAg mutant was made
in the breakthrough infection of a child born to a HBV-pos-
itive mother (16). The virus was vertically transmitted
despite the child’s being vaccinated and passively immu-
nized against HBV. The breakthrough viral strain was
DNAsequenced and shown to contain a substitution muta-
tion of glycine to arginine at HBsAg aa position 145
(Gly/Arg 145) (17). The child subsequently remained both
DNA- and HBsAg-positive for this Gly/Arg 145 mutant
for >12 years, despite having protective antibody to sur-
face antigen (anti-HBs) titer against the wild-type virus.
The Gly/Arg 145 substitution alters the projecting loop (aa
139–147) of the “a” determinant such that neutralizing
antibody induced by vaccination no longer recognizes the
mutated epitope, hence the term vaccine-escape mutant.
Wild-type HBsAg is reduced to undetectable levels in
these patient samples. For the vaccine-escape mutant to
emerge, the patient’s anti-HBs response must be localized
to the aa 139–147 region; the Gly/Arg 145 substitution
thus confers a selective advantage in viral replication, and
the mutant becomes the dominant form of the virus (18).
The replication of Gly/Arg 145 mutants has been investi-
gated with chimpanzee infection models. In the first study,
a wild-type HBV infection developed in chimpanzees
inoculated with a human sample of Gly/Arg 145 HBV;
only samples diluted >10–6 established mutant infection
(19). Since the pol gene ORF partially overlaps the S gene,
the Gly/Arg 145 mutation in the S gene sequence corre-
sponds to a Trp/Gln 153 mutation in the pol gene
sequence, which results in the expression of an altered
polymerase gene product. This altered polymerase is repli-
cation competent but has reduced replication efficiency
(6). When anti-HBs selection pressure is removed, wild-
type HBV returns as the predominant infectious form
because of the impeded replication of the Gly/Arg 145
mutant. These facts may explain why transmission studies
have failed to show mutant transmission to vaccinated ani-
mals (20). If the recipient animal had an anti-HBs response
directed against an epitope outside the aa 139–147 region,
the mutant inoculum would be neutralized by anti-HBs
binding to epitopes unaffected by the Gly/Arg 145 escape
mutation. In this case, no HBV infection would be estab-
lished. Since the emergence of the Gly/Arg 145 mutant is
constrained by requiring the host antibody response to be
directed solely against the aa 139–147 region, whether the
Gly/Arg 145 mutant will become the predominant infec-
tious form of HBV in the future, as some models have pre-
dicted (21), is questionable.
The Gly/Arg 145 substitution remains by far the pre-
dominant HBsAg mutant described in the literature (22).
However, a wide range of mutants have been described in
the past 10 years, including many amino acid substitution
mutants across the “a” determinant (23), amino acid inser-
tions into the “a” determinant (24,25), and deletion
mutants (7,26). Some of these substitution mutants appear
to be of academic interest as they occur at very low levels
in long-term HBV carriers and have only been identified
by highly directed DNAamplification techniques that used
primers specific for mutant sequence detection. The condi-
tions for performing highly amplified PCRs must include
controls to ensure that any sequence changes found are not
an artifact of PCR fidelity itself (27). Some HBV isolates
found in screening studies may be infrequently occurring
natural variants (28). Given the diversity of HBV geno-
types, the categorization of a novel HBsAg amino acid
change as a mutant should hinge on a tangible alteration in
viral function, such as antigenicity, infectivity, replication,
and morphology, which is attributable to the specific
change. One method for establishing a mutant is to intro-
duce the suspected amino acid change into a wild-type
backbone sequence and demonstrate altered function.
Important to the healthcare management of HBV infec-
tion is detection of HBsAg mutants by diagnostic assays.
HBsAg is a sentinel marker in blood bank donor screening
to prevent transmission of HBV infection in patients
receiving transfusions. A diagnostic assay used for HBV
screening may show false-negative results if the assay con-
figuration cannot detect mutants in the “a” determinant.
Initial reactivity data on 9 HBsAg assay configurations
determined for 28 defined and quantitated HBsAg recom-
binant mutant antigens (29) have been confirmed by sever-
al groups. In these studies, recombinant HBsAg antigens
containing a single amino acid substitution in an otherwise
wild-type sequence were tested for immunoassay reactivi-
ty. Since the level of protein expression varies greatly for
each recombinant HBsAg mutation, diluting each recom-
binant mutant protein to a known concentration before
immunoassay testing was important. By setting the con-
centration of each recombinant mutant sample well above
the antigen endpoint detection of the assays tested, the pos-
sibility of false-negative results caused by assay sensitivi-
ty was eliminated. Therefore, false-negative results were
due to failure to detect the mutated epitopes of the recom-
binant antigen. Recombinant HBsAg that represents com-
mon mutants found in neonatal breakthrough infections
was tested with different immunoassay formats (Table 1).
Substitution mutants in the projecting loop of the aa
139–147 region were not detected by some commercial
assays. Later generation HBsAg assays have enhanced
reagent configurations that allow them to detect not only
the common HBsAg mutants but also the rare mutations
that occur in the aa 121–124 region such as the Arg + Ala
123 insertion mutant (29). This mutant produces a 228-aa
surface antigen (instead of the wild-type 226 aa antigen)
with gross alteration of “a” determinant epitopes. This
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immunoassay format. In addition to the recombinant anti-
gens, 3 corresponding patient samples containing the
native HBsAg mutants were also available for testing. The
data indicated that the immunoreactivity of both the
recombinant antigen and the original patient sample were
the same. No wild-type antigen was detectable in the orig-
inal patient samples. Not quantitating recombinant HBsAg
mutant antigens before immunoassay evaluation can
account for some conflicting immunoassay detection
results published in subsequent studies (30). Moerman et
al. (31) have recently published an expanded selection of
immunoassays and their detection of the more common
HBsAg mutants (Table 2). Four commercially available
assays were tested with both recombinant antigens con-
taining defined mutations within the “a” determinant (sam-
ples 1–10) and with actual serum samples containing
HBsAg mutants (samples 11–14). Several assays detected
all of the mutant panel members, while others failed to
detect >1 panel member. The detection of recombinant
antigens paralleled the detection of patient serum samples.
Furthermore, only mutant HBsAg appears in the false-neg-
ative clinical samples, as wild-type antigen would have
been detected by the corresponding assays if present at suf-
ficient levels. Other investigators have also confirmed the
findings that some immunoassays are susceptible to the
common “a” determinant mutants and produce false-nega-
tive results (32). 
Case reports of false-negative diagnostic results due to
HBsAg mutants have been described in blood bank (33)
and hospital settings (34). The blood bank sample is of spe-
cial importance since this patient sample (containing a
Thr/Leu 143 mutant) was reported as HBsAg positive by 1
screening immunoassay, while a second screening
immunoassay reported the same sample as false-negative.
The Thr/Leu 143 mutant may be more prevalent than orig-
inally thought, as another occurrence has been recently
reported in Europe (35). Screening efforts should be under-
taken to establish the prevalence of this apparently emerg-
ing mutant and to establish its mechanism of selection. 
In most cases, investigators reporting false-negative
results due to HBsAg mutants recommend that laboratory
users of HBsAg assays be aware of a given assay’s ability
to detect mutants. An expert advisory meeting has recent-
ly issued a consensus report on emerging HBsAg mutants
(36). The meeting participants concluded that the preva-
lence of HBsAg mutants is probably higher than previous-
ly believed. The participants called for enhanced
surveillance efforts and data collection for mutants and
recommended using assays that detect the most frequently
observed mutants at aa positions 139–145. In addition,
users should develop an appropriate testing and confirma-
tory algorithm to ensure mutant detection. The prevalence
of HBsAg mutants can be established in laboratories that
perform sequential testing of a sample using 2 assays, each
with differing susceptibility to mutant false-negative
results. Discordant positive samples would be PCR ampli-
fied and sequenced to determine if a mutant sequence is
present. In a study in Singapore, the Gly/Arg 145 mutation
was present alone or in combination with other mutations
in 70% of the isolated HBsAg mutants from neonatal
breakthrough infections, for an overall mutant prevalence
of 4.6% in this population (37). A screening program for
school-age children in Taiwan found 27/3,849 patient sam-
ples with “a” determinant mutants for a prevalence of
0.7% (38). In India, testing of an HBV chronic carrier’s
household contacts found what might be the first docu-
mented case of Gly/Arg 145 horizontal transmission (39).
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rate in some populations and appears to be horizontally
transmissible, which suggests that HBV surveillance pro-
grams should use diagnostic methods capable of detecting
this mutant.
In contrast, substitutions at positions outside of the “a”
determinant appear to be readily detected by current com-
mercially available HBsAg immunoassays. For example,
mutations near the carboxy terminus of the small HBsAg
protein occur when polymerase mutations are selected for
in the YMDD reverse transcriptase domain (again well
outside the “a” determinant). Of greater interest are the
secondary compensatory changes emerging in polymerase
mutants (6). These “polymerase stabilizing” mutations are
expressed in HBsAg close to or in the “a” determinant and
reduce HBsAg immunoreactivity (40). The risk of a “sta-
bilized” polymerase mutant with altered HBsAg epitopes
(presumably from a patient on long-term nucleoside ana-
log treatment) being transmitted to a compatible recipient
is a key issue for diagnosticians to monitor in the future.
These mutants would potentially produce false-negative
test results in susceptible HBsAg immunoassays and yet
have the capacity to replicate in a manner similar to that of
wild-type virus. Reporting mutant occurrence at the
national level by using data-tracking to monitor regional
exposure would mitigate such a risk.
These studies of recombinant surface antigen mutants
underscore the usefulness of mapping the epitope suscep-
tibility of various commercially available HBsAg assays.
While testing of mutant panels is voluntary in some coun-
tries, certain regulatory agencies are becoming increasing-
ly aware of HBsAg mutants. In the United States,
manufacturers of new HBsAg assays must address mutant
detection in their package inserts. With a firm understand-
ing of immunoassay mutant detection, the diagnostician
can select the appropriate HBsAg screening algorithm to
minimize the impact of mutants in sentinel screening
programs.
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